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P R E V I E W SComing up for air:
HIF-1 and mitochondrial oxygen consumption
Hypoxic cells induce glycolytic enzymes; this HIF-1-mediated metabolic adaptation increases glucose flux to pyruvate and
produces glycolytic ATP. Two papers in this issue of Cell Metabolism (Kim et al., 2006; Papandreou et al., 2006) demonstrate
that HIF-1 also influences mitochondrial function, suppressing both the TCA cycle and respiration by inducing pyruvate de-
hydrogenase kinase 1 (PDK1). PDK1 regulation in hypoxic cells promotes cell survival.Oxygen deprivation (hypoxia) occurs in
tissues when O2 supply via the car-
diovascular system fails to meet the de-
mand of O2-consuming cells. Hypoxia
occurs naturally in physiological settings
(e.g., embryonic development and exer-
cising muscle), as well as in pathophysi-
ological conditions (e.g., myocardial in-
farction, inflammation, and solid tumor
formation). For over a century, it has
been appreciated that O2-deprived cells
exhibit increased conversion of glucose
to lactate (the ‘‘Pasteur effect’’). Activa-
tion of the Pasteur effect during hypoxia
in mammalian cells is facilitated by
HIF-1, which mediates the upregulation
of glycolytic enzymes that support an in-
crease in glycolytic ATP production as
mitochondria become starved for O2,
the substrate for oxidative phosphoryla-
tion (Seagroves et al., 2001). Thus, mito-
chondrial respiration passively decreases
due to O2 depletion in hypoxic tissues.
However, reports by Kim et al. (2006)
and Papandreou et al. (2006) in this issue
of Cell Metabolism demonstrate that this
critical metabolic adaptation is more
complex and includes an active suppres-
sion of mitochondrial pyruvate catabo-
lism and O2 consumption by HIF-1.
Mitochondrial oxidative phosphoryla-
tion is regulated by multiple mecha-
nisms, including substrate availability.
Major substrates include O2 (the terminal
electron acceptor) and pyruvate (the pri-
mary carbon source). Pyruvate, as the
end product of glycolysis, is converted150to acetyl-CoA by the pyruvate dehydro-
genase enzymatic complex and enters
the tricarboxylic acid (TCA) cycle. Pyru-
vate conversion into acetyl-CoA is irre-
versible; this therefore represents an im-
portant regulatory point in cellular energy
metabolism. Pyruvate dehydrogenase
kinase (PDK) inhibits pyruvate dehydro-
genase activity by phosphorylating its
E1 subunit (Sugden and Holness, 2003).
In the manuscripts by Kim et al. (2006)
and Papandreou et al. (2006), the authors
find that PDK1 is a HIF-1 target gene that
actively regulates mitochondrial respira-
tion by limiting pyruvate entry into the
TCA cycle. By excluding pyruvate from
mitochondrial metabolism, hypoxic cells
accumulate pyruvate, which is then con-
verted into lactate via lactate dehydroge-
nase (LDH), another HIF-1-regulated en-
zyme. Lactate in turn is released into the
extracellular space, regenerating NAD+
for continued glycolysis by O2-starved
cells (see Figure 1). This HIF-1-depen-
dent block to mitochondrial O2 con-
sumption promotes cell survival, espe-
cially when O2 deprivation is severe and
prolonged.
Papandreou et al. demonstrate that
hypoxic regulation of PDK has important
implications for antitumor therapies. Re-
cent interest has focused on cytotoxins
that target hypoxic cells in tumor micro-
environments, such as the drug tirapaz-
amine (TPZ). Because intracellular O2
concentrations are decreased by mito-
chondrial O2 consumption, HIF-1 couldprotect tumor cells from TPZ-mediated
cell death by maintaining intracellular O2
levels. Indeed, Papandreou et al. show
that HIF-1-deficient cells grown at 2%
O2 exhibit increased sensitivity to TPZ
relative to wild-type cells, presumably
due to higher rates of mitochondrial O2
consumption. HIF-1 inhibition in hypoxic
tumor cells should have multiple thera-
peutic benefits, but the use of HIF-1 in-
hibitors in conjunction with other treat-
ments has to be carefully evaluated for
the most effective combination and se-
quence of drug delivery. One result of
HIF-1 inhibition would be a relative de-
crease in intracellular O2 levels, making
hypoxic cytotoxins such as TPZ more
potent antitumor agents. Because PDK
expression has been detected in multiple
human tumor samples and appears to be
induced by hypoxia (Koukourakis et al.,
2005), small molecule inhibitors of HIF-1
combined with TPZ represent an attrac-
tive therapeutic approach for future clini-
cal studies.
Hypoxic regulation of PDK1 has other
important implications for cell survival
duringO2depletion.Because theTCAcy-
cle is coupled to electron transport, Kim
et al. suggest that induction of the pyru-
vate dehydrogenase complex by PDK1
attenuates not only mitochondrial respi-
ration but also the production of mito-
chondrial reactive oxygen species (ROS)
in hypoxic cells. ROS are a byproduct
of electron transfer to O2, and cells cul-
tured at 1 to 5% O2 generate increasedCELL METABOLISM : MARCH 2006
P R E V I E W Smitochondrial ROS relative to those cul-
tured at 21% O2 (Chandel et al., 1998;
Guzy et al., 2005). In fact, hypoxia-in-
duced mitochondrial ROS have also
been shown tobenecessary for the stabi-
lization of HIF-1 in hypoxic cells (Brunelle
et al., 2005; Guzy et al., 2005; Mansfield
et al., 2005). However, the persistence
of ROS could ultimately be lethal to tis-
sues during chronic O2 deprivation, and
PDK1 induction by HIF-1 should promote
cell viability during long-term hypoxia.
Kim et al. present evidence that HIF-1-
deficient cells exhibit increased apopto-
sis after 72 hr of culture at 0.5% O2 com-
pared to wild-type cells and that cell
survival is rescued by enforced expres-
sion of exogenous PDK1. Furthermore,
PDK1 reduces ROS production by the
HIF-1 null cells. These findings support
a novel prosurvival dimension of cellular
hypoxic adaptation where PDK1 inhibits
the TCA cycle, mitochondrial respiration,
and chronic ROS production.
The HIF-1-mediated block to mito-
chondrial O2 consumption via PDK1 reg-
ulation also has implications for O2-sens-
ing pathways by hypoxic cells. One
school of thought suggests that perturb-
ing mitochondrial O2 consumption in-
creases intracellular O2 concentrations
and suppresses HIF-1 induction by
promoting the activity of HIF prolyl hy-
droxylases, the O2-dependent enzymes
that regulate HIF-1 stability (Hagen
et al., 2003; Doege et al., 2005). This
model suggests that mitochondria func-
tion as ‘‘O2 sinks.’’ Although Papandreou
et al. demonstrate that increased mito-
chondrial respiration due to PDK1 deple-
tion results in decreased intracellular O2
levels (based on pimonidazole staining),
these changes failed to reduce HIF-1
levels in hypoxic cells. Another model
for hypoxic activation of HIF-1 describes
a critical role for mitochondrial ROS in
prolyl hydroxylase inhibition and HIF-1
stabilization in O2-starved cells (Brunelle
et al., 2005; Guzy et al., 2005; Mansfield
et al., 2005) (see Figure 1). The mitochon-
drial ‘‘O2 sink’’ hypothesis can account
for some observations in the literature
but fails to explain the inhibition of
HIF-1 stabilization by ROS scavengers
(Chandel et al., 1998; Brunelle et al.,
2005; Guzy et al., 2005; Sanjua´n-Pla
et al., 2005). While the relationship be-
tween HIF-1 stability, mitochondrial me-
tabolism, ROS, and intracellular O2 redis-CELL METABOLISM : MARCH 2006Figure 1. Multiple hypoxia-induced cellular metabolic changes are regulated by HIF-1
By stimulating the expression of glucose transporters and glycolytic enzymes, HIF-1 promotes glycolysis to
generate increased levels of pyruvate. In addition, HIF-1 promotes pyruvate reduction to lactate by activating
lactate dehydrogenase (LDH). Pyruvate reduction to lactate regenerates NAD+, which permits continued gly-
colysis and ATP production by hypoxic cells. Furthermore, HIF-1 induces pyruvate dehydrogenase kinase 1
(PDK1), which inhibits pyruvate dehydrogenase and blocks conversion of pyruvate to acetyl CoA, resulting
in decreased flux through the tricarboxylic acid (TCA) cycle. Decreased TCA cycle activity results in attenua-
tion of oxidative phosphorylation and excessive mitochondrial reactive oxygen species (ROS) production. Be-
cause hypoxic cells already exhibit increased ROS, which have been shown to promote HIF-1 accumulation,
the induction of PDK1 prevents the persistence of potentially harmful ROS levels.tribution will continue to be debated for
some time, these most recent findings
shed new light on findings by Louis Pas-
teur over a century ago.
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